Hollywood Mark's Form 4 filing
Zymeworks Inc. (ZYME) · filed Jan 13, 2026
- Accession no.
- 0001193125-26-011885
- Filed
- Jan 13, 2026
- Trade date
- Jan 12, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 4 derivative transactions. Open-market sales total $138.7K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hollywood MarkCIK 0002104446 | Officer (EVP & Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | Common Stock | MOption exerciseDisposed | −17,666 | $0.00 | $0 | 35,334 | Direct | |
| Jan 12, 2026 | Common Stock | AGrant or awardAcquired | +70,000 | $0.00 | $0 | 70,000 | Direct | |
| Jan 12, 2026 | Common Stock | AGrant or awardAcquired | +47,000 | $0.00 | $0 | 47,000 | Direct | |
| Jan 12, 2026 | Common Stock | AGrant or awardAcquired | +66,000 | $0.00 | $0 | 66,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 10, 2025.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.